Document is current

Any future updates will be listed below

Spiramycin—A BCS Class III Drug: Comparative Studies On the Development of Lipid-based Nano Formulations for Improved Oral Bioavailability and Antibacterial Action

Crossref DOI link: https://doi.org/10.1007/s12247-026-10727-3

Published Online: 2026-05-11

Published Print: 2026-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark